Patents by Inventor Sivaraman Dandapani
Sivaraman Dandapani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220340557Abstract: The present disclosure provides compounds of Formula (I?), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: ApplicationFiled: November 22, 2021Publication date: October 27, 2022Applicants: Memorial Sloan-Kettering Cancer Center, The Regents of the University of California, University of Central Florida Research Foundation, Inc., The Broad Institute, Inc.Inventors: Derek Shieh Tan, Corinne N. Foley, Gustavo Moura-Letts, James McKerrow, Sivaraman Dandapani, Rahul Edwankar, Alyssa Verano, Debopam Chakrabarti, Bracken Roberts
-
Publication number: 20220290140Abstract: Featured are trans-cyclooctene and tetrazine compounds. Also provided are methods for evaluating the biodistribution and/or concentration of a biomolecule in a subject.Type: ApplicationFiled: August 19, 2020Publication date: September 15, 2022Inventors: Brendon Ellery COOK, Maciej Adam KALISZCZAK, Laurent MARTARELLO, Nathan Edward GENUNG, Sivaraman DANDAPANI, Eric Edward SWAYZE, William John DRURY, III, Chrissa Ann DWYER
-
Publication number: 20220160702Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.Type: ApplicationFiled: June 10, 2021Publication date: May 26, 2022Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
-
Patent number: 11180492Abstract: The present disclosure provides compounds of Formula (I?), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: GrantFiled: January 17, 2017Date of Patent: November 23, 2021Assignees: University of Central Florida Research Foundation, Inc., The Regents of the University of California, Memorial Sloan-Kettering Cancer Center, The Broad Institute, Inc.Inventors: Derek Shieh Tan, Corinne N. Foley, Gustavo Moura-Letts, James McKerrow, Sivaraman Dandapani, Rahul Edwankar, Alyssa Verano, Debopam Chakrabarti, Bracken Roberts
-
Patent number: 11052080Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.Type: GrantFiled: November 21, 2018Date of Patent: July 6, 2021Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
-
Publication number: 20200140425Abstract: Disclosed are compounds that can be used for treating tuberculosis.Type: ApplicationFiled: April 10, 2019Publication date: May 7, 2020Inventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate
-
Publication number: 20200061050Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.Type: ApplicationFiled: November 21, 2018Publication date: February 27, 2020Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
-
Publication number: 20190175584Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.Type: ApplicationFiled: November 21, 2018Publication date: June 13, 2019Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
-
Patent number: 10301294Abstract: Disclosed are compounds that can be used for treating tuberculosis.Type: GrantFiled: March 12, 2014Date of Patent: May 28, 2019Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS GENERAL HOSPITAL, BRIGHAM AND WOMEN'S HOSPITALInventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate
-
Publication number: 20190002463Abstract: The present disclosure provides compounds of Formula (I?), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: ApplicationFiled: January 17, 2017Publication date: January 3, 2019Applicants: Memorial Sloan-Kettering Cancer Center, The Regents of The University of California, University of Central Florida Research Foundation, Inc., The Broad Institute, Inc.Inventors: Derek Shieh Tan, Corinne N. Foley, Gustavo Moura-Letts, James McKerrow, Sivaraman Dandapani, Rahul Edwankar, Alyssa Verano, Debopam Chakrabarti, Braken Roberts
-
Patent number: 10137122Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.Type: GrantFiled: July 14, 2015Date of Patent: November 27, 2018Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
-
Patent number: 10064853Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.Type: GrantFiled: June 26, 2017Date of Patent: September 4, 2018Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
-
Patent number: 9951055Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.Type: GrantFiled: October 21, 2013Date of Patent: April 24, 2018Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc.Inventors: Chris Dockendorff, Willmen Youngsaye, Partha Pratim Nag, Timothy A. Lewis, Sivaraman Dandapani, Benito Munoz, Patrick Faloon, Thomas Nieland, Monty Krieger, Miao Yu
-
Patent number: 9944607Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrate, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive Compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoan, or inhibiting the growth of a fungus or protozoan. The fungus may be a Candida species, Sacchawmyces species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan mitochondrial phosphate carrier protein.Type: GrantFiled: October 16, 2013Date of Patent: April 17, 2018Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, The Broad Institute, Inc.Inventors: Benjamin Vincent, Luke Whitesell, Susan L. Lindquist, Willmen Youngsaye, Stephen L. Buchwald, Jean-Baptiste Langlois, Jun Pu, Benito Munoz, Sivaraman Dandapani
-
Patent number: 9884851Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein R1 and R2 are independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or R1 and R2 together are —O—CH2— or —O—CF2—O—; R3 is H, halogen, cyano, haloalkyl or haloalkyloxy; R4 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl or C3-6cycloheteroalkyl, wherein the heteroatom is N or O; R5 is H or CH3; R6 is C1-6alkyl or C3-6cycloalkyl; and A, B, D and E are each, independently, CH, N, O or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, O or S.Type: GrantFiled: October 21, 2013Date of Patent: February 6, 2018Assignees: Massachusetts Institute Of Technology, The Broad Institute, Inc.Inventors: Chris Dockendorff, Andrew Germain, Partha Pratim Nag, Willmen Youngsaye, Sivaraman Dandapani, Benito Munoz, Patrick Faloon, Thomas Nieland, Monty Krieger, Miao Yu
-
Publication number: 20170304283Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I).Type: ApplicationFiled: June 26, 2017Publication date: October 26, 2017Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
-
Patent number: 9738610Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoon, or inhibiting the growth of a fungus or protozoon. The fungus may be a Candida species, Aspergillus species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan cytochrome b and/or fungal or protozoan Hsp90. The present invention also provides synthetic methods of the inventive compounds.Type: GrantFiled: September 24, 2013Date of Patent: August 22, 2017Assignees: Whitehead Institute for Biomedical Research, The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Benjamin Vincent, Luke Whitesell, Susan L. Lindquist, Willmen Youngsaye, Stephen L. Buchwald, Jean-Baptiste Langlois, Partha P. Nag, Amal Ting, Barbara J. Morgan, Benito Munoz, Sivaraman Dandapani, Bruce Tidor, Raja R. Srinivas
-
Publication number: 20160145209Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.Type: ApplicationFiled: June 20, 2014Publication date: May 26, 2016Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz
-
Publication number: 20160060254Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.Type: ApplicationFiled: October 21, 2013Publication date: March 3, 2016Inventors: Chris Dockendorff, Willmen Youngsaye, Partha Pratim Nag, Timothy A. Lewis, Sivaraman Dandapani, Benito Munoz, Patrick Falloon, Thomas Nieland, Monty Krieger, Miao Yu
-
Publication number: 20160031870Abstract: Disclosed are compounds that can be used for treating tuberculosis.Type: ApplicationFiled: March 12, 2014Publication date: February 4, 2016Inventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate